67 results
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Ordinary shares | Deferred shares | Additional Paid-in | Accumulated | Total Shareholders’ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balance, January 1, 2023 | 949,958 | £ | 95 | 794,955 | £ | 397,398 | £ | 33,308,568 | £ | (33,374,796) | £ | 331,265 | ||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation expense | - | - | - | - | 139,815 | 139,815 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of ordinary shares, net of issuance costs | 1,530,000 | 153 | - | - | 1,280,296 | - | 1,280,449 | Net loss | - | - | - | - | - | (634,911) | (634,911) | |||||||||||||||||||||||||||||||||||||||||
Balance, March 31, 2023 | 2,479,958 | £ | 248 | 794,955 | £ | 397,398 | £ | 34,728,679 | £ | (34,009,707) | £ | 1,116,618 |
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
For the Three Months Ended | For the Three Months Ended | |||||||
March 31, 2024 | March 31, 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | £ | (3,321,854) | £ | (634,911) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 114,745 | 169,155 | ||||||
Amortization of intangible assets | 12,276 | 11,815 | ||||||
Share-based compensation expense | 784,555 | 139,815 | ||||||
Change in fair value of derivative liability | (11,446) | (3,148,648) | ||||||
Offering costs satisfied by issue of Series C Placement Agent Warrants | - | 219,830 | ||||||
Net foreign exchange loss | - | (17,214) | ||||||
Noncash interest expense | - | 11,705 | ||||||
Changes in operating assets and liabilities: | ||||||||
Change in corporation tax receivable | (110,742) | (400,000) | ||||||
Change in prepaid expenses and other current assets | 127,236 | 332,510 | ||||||
Change in operating lease right of use assets | 48,061 | 46,211 | ||||||
Change in accounts payable and accrued liabilities | 21,607 | 447,418 | ||||||
Change in lease liabilities | (73,031) | (88,933) | ||||||
Net cash used in operating activities | (2,408,593) | (2,911,247) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchase of property and equipment | - | (120,182) | ||||||
Purchase of intangible assets | (5,618) | (25,051) | ||||||
Net cash used in investing activities | (5,618) | (145,233) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Series D warrant exercises | 986,772 | - | ||||||
Proceeds from sale of warrants | - | 2,673,789 | ||||||
Issuance of ordinary shares | 19,765 | 1,439,414 | ||||||
Ordinary shares and warrant issuance costs | (73,980) | (158,965) | ||||||
Net cash provided by financing activities | 932,557 | 3,954,238 | ||||||
NET CHANGE IN CASH | (1,481,654) | 897,758 | ||||||
Cash - Beginning of period | 2,462,609 | 4,808,060 | ||||||
Cash - End of period | £ | 980,955 | £ | 5,705,818 |
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
March 31, 2024 | December 31, 2023 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | £ | 980,955 | £ | 2,462,609 | ||||
Corporation tax receivable | 1,154,335 | 1,043,593 | ||||||
Prepaid expenses and other current assets | 2,067,490 | 2,194,725 | ||||||
Total current assets | 4,202,780 | 5,700,927 | ||||||
Non-current assets: | ||||||||
Property and equipment, net | 1,160,053 | 1,274,798 | ||||||
Operating lease right of use assets | 1,292,708 | 1,340,769 | ||||||
Intangible assets, net | 608,512 | 615,170 | ||||||
Total assets | 7,264,053 | 8,931,664 | ||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | 4,453,447 | 4,431,840 | ||||||
Derivative liability | 1,991 | 13,437 | ||||||
Current portion of operating lease liability | 308,158 | 305,324 | ||||||
Total current liabilities | 4,763,596 | 4,750,601 | ||||||
Non-current operating lease liability | 1,419,969 | 1,495,833 | ||||||
Total liabilities | 6,183,565 | 6,246,434 | ||||||
Shareholders’ Equity: | ||||||||
Ordinary shares, £0.0001 par value, 63,902,641 and 20,570,088 authorized, issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 6,391 | 2,057 | ||||||
Deferred shares, £0.0001 par value, 794,955 and 794,955 authorized, issued, and outstanding as of March 31, 2024 and December 31, 2023, respectively | 397,398 | 397,398 | ||||||
Additional paid-in capital | 42,835,843 | 41,123,065 | ||||||
Accumulated deficit | (42,159,144) | (38,837,290) | ||||||
Total shareholders’ equity | 1,080,488 | 2,685,230 | ||||||
Total liabilities and shareholders’ equity | £ | 7,264,053 | £ | 8,931,664 |
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
Ordinary shares | Deferred shares | Additional Paid-in | Accumulated | Total Shareholders’ | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
Balance, January 1, 2024 | 20,570,088 | £ | 2,057 | 794,955 | £ | 397,398 | £ | 41,123,065 | £ | (38,837,290) | £ | 2,685,230 | ||||||||||||||||
Balance | 20,570,088 | £ | 2,057 | 794,955 | £ | 397,398 | £ | 41,123,065 | £ | (38,837,290) | £ | 2,685,230 | ||||||||||||||||
Share-based compensation expense | 2,421,400 | 242 | - | - | 784,555 | 784,797 | ||||||||||||||||||||||
Shares issued in connection with Series D warrant exercise, net of issuance costs | 12,475,000 | 1,248 | - | - | 911,544 | - | 912,792 | |||||||||||||||||||||
Issuance of ordinary shares | 28,436,153 | 2,844 | - | - | 16,679 | - | 19,523 | |||||||||||||||||||||
Net loss | - | - | - | - | - | (3,321,854) | (3,321,854) | |||||||||||||||||||||
Balance, March 31, 2024 | 63,902,641 | £ | 6,391 | 794,955 | £ | 397,398 | £ | 42,835,843 | £ | (42,159,144) | £ | 1,080,488 | ||||||||||||||||
Balance | 63,902,641 | £ | 6,391 | 794,955 | £ | 397,398 | £ | 42,835,843 | £ | (42,159,144) | £ | 1,080,488 |
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
March 31, 2024 | December 31, 2023 | |||||||
Exercise price | $ | 125.00 | $ | 125.00 | ||||
Share price | $ | 1.31 | $ | 3.17 | ||||
Time to maturity | 4.17 years | 4.4 years | ||||||
Expected volatility | 90 | % | 90 | % | ||||
Risk free interest rate (US treasury bond) | 3.9 | % | 4.0 | % | ||||
- | - |
10-Q
1inefr
15 May 24
Quarterly report
4:06pm
10-Q
ckh7aui
15 May 24
Quarterly report
4:06pm
10-Q
39kihyfiyr l310leghp
15 May 24
Quarterly report
4:06pm
10-Q
izei3l9d8v4gtv4
15 May 24
Quarterly report
4:06pm
10-Q
z5koigg9v q2yaus5pmm
15 May 24
Quarterly report
4:06pm
10-Q
twg3cftv x1da
15 May 24
Quarterly report
4:06pm
10-Q
i8bax6gwdzf8e ig
15 May 24
Quarterly report
4:06pm
10-Q
ilyr ruoh
15 May 24
Quarterly report
4:06pm
10-Q
xzn heg53
15 May 24
Quarterly report
4:06pm
10-Q
r9f71qmjnjuio4ck
15 May 24
Quarterly report
4:06pm
10-Q
8vp95kkk41njbby7fhj
15 May 24
Quarterly report
4:06pm
10-Q
r40ix 1gjexwto
15 May 24
Quarterly report
4:06pm
10-Q
ipfy0u5p8dz38p0y2f7p
15 May 24
Quarterly report
4:06pm
10-Q
ugq7a6t
15 May 24
Quarterly report
4:06pm
10-Q
jcyim
15 May 24
Quarterly report
4:06pm